GlassScriptPhysician profile
Ronda L Bloom
NPI 1447210703
$2,279.93
in general payments reported to CMS, 2019-2025
28 companies · $229 in 2025
The $229 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $712 · 2020: $426 · 2022: $11.71 · 2023: $362 · 2024: $539 · 2025: $229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,085 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,084.97 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $311.03 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $282.03 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $268.03 | 2019-2020 | |
| Amgen INC. | $160.92 | 2019-2025 | Repatha, Evenity |
| Abbvie INC. | $146.43 | 2019-2025 | Synthroid |
| Xeris Pharmaceuticals, INC. | $145.31 | 2020-2024 | Gvoke Hypopen, Recorlev |
| Radius Health, INC. | $132.58 | 2020-2025 | Tymlos |
| Mannkind Corporation | $86.58 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $82.99 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $81.85 | 2023-2025 | |
| Abbott Laboratories | $78.67 | 2020-2024 | Freestyle Libre 3 |
| Ibsa Pharma INC. | $55.09 | 2023-2025 | Tirosint, Licart, Flector |
| Avvisto Therapeutics, LLC | $49.11 | 2024 | Cycloset |
| Merck Sharp & Dohme LLC | $47.93 | 2019-2020 | |
| Medtronic Minimed, INC. | $43.38 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $40.86 | 2023-2024 | Unithroid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.74 | 2019-2020 | |
| Antares Pharma, INC. | $37.56 | 2019-2024 | Xyosted |
| Amarin Pharma, INC. | $36.83 | 2020 | |
| Corcept Therapeutics | $22.67 | 2023 | Korlym |
| Medtronic, INC. | $22.34 | 2023 | Minimed 780g |
| Ascendis Pharma Endocrinology INC | $20.00 | 2025 | Yorvipath |
| Valeritas, INC. | $16.62 | 2019 | |
| Alexion Pharmaceuticals, INC. | $16.48 | 2019 | |
| Astellas Pharma US INC | $15.26 | 2023 | Veozah |
| Tandem Diabetes Care, INC. | $14.03 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Averitas Pharma INC. | $13.61 | 2023 | Qutenza |
| Arbor Pharmaceuticals, INC. | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronda Bloom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.